Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eisai Sees Generics Production In India Way To Make Affordable Drugs (Japan)

This article was originally published in PharmAsia News

Executive Summary

An Eisai executive says the Japanese company is turning to India for expanded production of active pharmaceutical ingredients, in part because it cannot make drugs in Japan cheaply enough to make them affordable in poor countries. Takafumi Asano, an Esai vice president, also said the company expects to take advantage of production costs in India to make its own generics at a fraction of the price of its branded drugs. Asano added, during an interview along with Deputy President Soichi Matsuno, that the company would not be able to do so if it relied solely on its Kashima plant in Japan. The firm recently opened a second production plant for generics in India. (Click here for more - may require a subscription

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel